<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Differential diagnosis of viral exanthems in children</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Viral exanthem</th>
    <th>Etiology/infectivity</th>
    <th>Clinical manifestations/incubation period (IP)</th>
    <th>Diagnostic methods</th>
    <th>Treatment</th>
    <th>Prevention</th>
    <th>Complications</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="7">
     <bold>I macular and maculopapular</bold>
     <bold>exanthems</bold>
    </td>
   </tr>
   <tr>
    <td>
     <p>
      <bold>Measles</bold>
     </p>
     <p>( 
      <bold>rubeola</bold>)
     </p>
     <p>[
      <xref ref-type="bibr" rid="CR22">22</xref>, 
      <xref ref-type="bibr" rid="CR23">23</xref>]
     </p>
    </td>
    <td>RNA measles virus/highly contagious</td>
    <td>
     <p>IP:10–12 days</p>
     <p>Prodrome: fever, coryza, conjunctivitis, rhinorrhea, sore throat, and a dry cough</p>
     <p>Enanthem: Koplik’ s spots</p>
     <p>Exanthem: 3–4 days later, begins behind the ears and hairline area, spreads over the rest of the skin over few days, resolves in the same order as its appearance, and will often desquamate</p>
    </td>
    <td>
     <p>Clinical presentation</p>
     <p>Serum measles IGM test for confirmation</p>
    </td>
    <td>
     <p>No specific antiviral therapy for measles</p>
     <p>Treatment of symptoms</p>
    </td>
    <td>Measles vaccine alone or as part of MMR vaccine</td>
    <td>
     <p>Transient immune suppression</p>
     <p>Acute postinfectious encephalitis</p>
     <p>Subacute sclerosing panencephalitis (SSPE)</p>
    </td>
   </tr>
   <tr>
    <td>
     <p>
      <bold>Rubella</bold>
     </p>
     <p>( 
      <bold>German measles</bold>)
     </p>
     <p>[
      <xref ref-type="bibr" rid="CR22">22</xref>, 
      <xref ref-type="bibr" rid="CR24">24</xref>]
     </p>
    </td>
    <td>RNA rubella virus/highly contagious</td>
    <td>
     <p>IP: 3–4 weeks</p>
     <p>Prodromal symptoms, which include low-grade fever, headache, sore throat, and myalgias</p>
     <p>Exanthema stage: appears after 2–5 days and spreads in a cephalocaudal pattern</p>
     <p>Symmetrical lymphadenopathy in postauricular and occipital areas, arthralgias, and arthritis</p>
    </td>
    <td>Serum rubella IGM titer test</td>
    <td>
     <p>No specific antiviral therapy for rubella</p>
     <p>Supportive treatment</p>
    </td>
    <td>Rubella vaccine alone or part of MMR vaccine</td>
    <td>Congenital rubella syndrome (deafness, cataracts, and cardiac disease)</td>
   </tr>
   <tr>
    <td>
     <p>
      <bold>Erythema infectiosum</bold>
     </p>
     <p>( 
      <bold>fifth disease</bold>)
     </p>
     <p>[
      <xref ref-type="bibr" rid="CR22">22</xref>]
     </p>
    </td>
    <td>DNA Parvovirus B19</td>
    <td>
     <p>IP: 1–2 weeks</p>
     <p>First stage: fiery-red facial erythema (slapped cheeks)</p>
     <p>Second stage: 3–4 days later (rash over proximal extremities)</p>
     <p>Third stage: exanthem recurs intermittently in response to stimuli (local irritation, high temperatures, and emotional stress)</p>
     <p>Asymmetric large joint arthropathy (10 % of patients)</p>
    </td>
    <td>
     <p>Clinical Diagnosis</p>
     <p>ELISA test highly sensitive; however, false positive results may recur</p>
     <p>PCR test is available</p>
    </td>
    <td>
     <p>Supportive</p>
     <p>At-risk patients may require transfusions or intravenous immunoglobulin therapy</p>
    </td>
    <td>
     <p>No specific preventive measure</p>
     <p>Handwashing might be helpful during epidemics</p>
    </td>
    <td>Transient aplastic crisis, chronic red cell aplasia, hydrops fetalis, or congenital anemia</td>
   </tr>
   <tr>
    <td>
     <bold>Roseola infantum</bold>
    </td>
    <td>Human herpesvirus (HHV) types 6 and 7</td>
    <td>
     <p>IP:5–15 days</p>
     <p>High fever (3–5 days),followed by the acute onset of a rosy pink, nonpruritic macular rash, predominantly on the neck and trunk; leukopenia</p>
    </td>
    <td>
     <p>Clinical diagnosis</p>
     <p>No available standardized lab test</p>
    </td>
    <td>Supportive treatment</td>
    <td>No specific preventive measures</td>
    <td>Febrile seizures</td>
   </tr>
   <tr>
    <td colspan="7">
     <bold>II vesicular and pustular</bold>
     <bold>exanthems</bold>
    </td>
   </tr>
   <tr>
    <td>
     <p>
      <bold>Varicella</bold>
     </p>
     <p>( 
      <bold>chickenpox</bold>)
     </p>
     <p>[
      <xref ref-type="bibr" rid="CR22">22</xref>, 
      <xref ref-type="bibr" rid="CR25">25</xref>]
     </p>
    </td>
    <td>
     <p>DNA varicella zoster virus (VZV) </p>
     <p>Highly contagious during IP and active skin rash</p>
    </td>
    <td>
     <p>IP: 2–3 weeks</p>
     <p>Two different clinical presentations:</p>
     <p>Varicella manifestations:</p>
     <p>Prodromal stage: fever, malaise, and myalgias</p>
     <p>Exanthem stage: begins in the hairline and spreads in a cephalocaudal pattern, involving the scalp and mucous membranes, vesicle crust (within 4–5 days of onset of the initial lesion), older lesion crust over as newer lesions form (polymorphous exanthema); lesions may heal with hypopigmentation and scarring</p>
     <p> Herpes zoster (shingles) manifestation: unilateral vesicular skin eruption involving one to three dermatomes, may be painful or pruritic</p>
     <p>Usually a benign, mild, self-limiting disease (in immunocompetent individuals)</p>
    </td>
    <td>
     <p>Clinical Diagnosis</p>
     <p>Can be confirmed by skin scraping testing for the antigen with immunofluorescence</p>
    </td>
    <td>
     <p>Oral acyclovir (ACV) is not routinely recommended except for adolescents (for 5 days, starting within 24 h of rash development)</p>
     <p>Symptomatic treatment for fever (only use acetaminophen) and pruritus (calamine lotion and colloidal oatmeal baths)</p>
    </td>
    <td>Varicella vaccine</td>
    <td>
     <p>Immunocompetent children: bacterial superinfection, due to group A 
      <italic>Streptococcus</italic> or 
      <italic>Staphylococcus aureus</italic>
     </p>
     <p>Immunocompromised patients are at risk for severe and protracted varicella, multiorgan involvement, and hemorrhagic varicella</p>
    </td>
   </tr>
   <tr>
    <td>
     <p>
      <bold>Hand, foot, and mouth</bold>
     </p>
     <p>
      <bold>disease (HFMD)</bold>
     </p>
     <p>[
      <xref ref-type="bibr" rid="CR22">22</xref>]
     </p>
    </td>
    <td> Coxsackie A16 virus, other Coxsackie, and enteroviruses</td>
    <td>
     <p>IP: 3–7 days</p>
     <p>Prodrome: fever, lymphadenopathy</p>
     <p>Exanthem: 1–2 days later painful vesicles on the palmar and plantar skin, buccal mucosa, and tongue</p>
     <p>Resolves in 5–7 days</p>
    </td>
    <td>
     <p>Is a clinical diagnosis</p>
     <p>Can be confirmed by isolating the virus from vesicles</p>
    </td>
    <td>
     <p>No specific treatment</p>
     <p>Symptomatic</p>
    </td>
    <td>
     <p>No specific measures</p>
     <p>Handwashing, surface cleaning, and disinfection</p>
    </td>
    <td>Rare: neurological or cardiopulmonary complication (meningoencephalitis or myocarditis)</td>
   </tr>
   <tr>
    <td colspan="7">
     <bold>III Papular exanthem</bold>, 
     <bold>e.g.,</bold>
     <bold>papular acrodermatitis of childhood (PAC)</bold>[
     <xref ref-type="bibr" rid="CR22">22</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="7">
     <bold>IV Other viral exanthems</bold>, 
     <bold>e.g., pityriasis</bold>
     <bold>rosea</bold>, 
     <bold>erythema multiforme</bold>, 
     <bold>nonspecific viral exanthems</bold> [
     <xref ref-type="bibr" rid="CR22">22</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
